Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities

Código QR

Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities

SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaodong Tian, Wenguo Jiang, He Zhang, XiXi Lu, Libo Li, Wenjun Liu, Jing Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 SARS-CoV-2 antibody response asymptomatic infection persistence Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/2039b69561a94ffba6a6540040479082
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning
por: Shira Doron, et al.
Publicado: (2021)

Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
por: Olivier Bylicki, et al.
Publicado: (2021)

Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
por: Brandon J. Beddingfield, et al.
Publicado: (2021)

Antibody Responses to SARS-CoV-2 Infection—Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA
por: Dinesh Mohanraj, et al.
Publicado: (2021)

Development and Clinical Application of a Rapid and Sensitive Loop-Mediated Isothermal Amplification Test for SARS-CoV-2 Infection
por: Xuejiao Hu, et al.
Publicado: (2020)

Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
por: Karolina Pieniawska-Śmiech, et al.
Publicado: (2021)

In-Depth Longitudinal Comparison of Clinical Specimens to Detect SARS-CoV-2
por: Justine Defêche, et al.
Publicado: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
por: Chin-Shern Lau, et al.
Publicado: (2021)

Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients
por: Huan Han, et al.
Publicado: (2020)

Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain
por: Carlota Dobaño, et al.
Publicado: (2021)

SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures
por: Amir Barzin, et al.
Publicado: (2020)

Factors affecting SARS-CoV-2 (COVID-19) Pandemic, including Zoonotic, Human Transmission and Chain of Infection. Reducing Public health Risk by Serum Antibody Testing, Avoiding Screening in Unhygienic Places and False PCR Reporting. A Scientific Review
por: Kamran Mahmood Ahmed Aziz, et al.
Publicado: (2021)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
por: Doris Urlaub, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Lin Yang, et al.
Publicado: (2021)

Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
por: Xie C, et al.
Publicado: (2021)

Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19
por: Helena Codina, et al.
Publicado: (2021)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Frank-Peter Tillmann, et al.
Publicado: (2021)

Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
por: Cheng Xiao, et al.
Publicado: (2021)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <italic toggle="yes">In Vivo</italic> in a Mouse Model in a Neutralization-Dependent Manner
por: Fatima Amanat, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Constant Gillot, et al.
Publicado: (2021)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Kevin J Selva, et al.
Publicado: (2021)

Pervasive RNA Secondary Structure in the Genomes of SARS-CoV-2 and Other Coronaviruses
por: P. Simmonds
Publicado: (2020)

Investigating Adherence to COVID-19 Vaccination and Serum Antibody Concentration among Hospital Workers—The Experience of an Italian Private Hospital
por: Guglielmo Forgeschi, et al.
Publicado: (2021)

Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS
por: Lili Zhao, et al.
Publicado: (2021)

Studying Humoral Immune Response at Mild and Asymptomatic COVID-19 Forms
por: S. V. Balakhonov, et al.
Publicado: (2020)

Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
por: Kim J. Hasenkrug, et al.
Publicado: (2021)

Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay
por: Alanoud Alshami, et al.
Publicado: (2021)

Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic
por: A. Yu. Popova, et al.
Publicado: (2021)

Asymptomatic COVID-19 Patients Can Contaminate Their Surroundings: an Environment Sampling Study
por: Li Wei, et al.
Publicado: (2020)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Sua Lee, et al.
Publicado: (2021)

Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for Accurate and Prompt Coronavirus Disease 2019 (COVID-19) Diagnosis Using the Rational Selection of Serological Biomarkers
por: Theano Lagousi, et al.
Publicado: (2021)

Antibody cocktail effective against variants of SARS-CoV-2
por: Kang-Hao Liang, et al.
Publicado: (2021)

Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
por: Alexandre Marchand, et al.
Publicado: (2021)

Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant
por: Ravi Kant, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys
por: Seif Salem Al-Abri, et al.
Publicado: (2021)

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
por: Bernard Vanhove, et al.
Publicado: (2021)

Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine
por: Taweewun Hunsawong, et al.
Publicado: (2021)

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
por: Indrė Kučinskaitė-Kodzė, et al.
Publicado: (2021)

High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2
por: Rita Jaafar, et al.
Publicado: (2021)